Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2008
Business Overview: Neurocrine discovers, develops, and intends to commercialize drugs for neurological and endocrine-related diseases. The company has eight programs in various stages of research and development, with five in clinical development. Key programs include a GnRH candidate for endometriosis and collaborations with GlaxoSmithKline (GSK) and Dainippon Sumitomo Pharma Co. Ltd (DSP).
Key Financial Metrics
| Metric | Q1 2008 | Q1 2007 |
|---|---|---|
| Total Revenues | $1.8 million | $0.1 million |
| Net Loss | $(21.1) million | $(25.7) million |
| Loss Per Share (Basic & Diluted) | $(0.55) | $(0.68) |
| Operating Expenses | $22.5 million | $27.4 million |
| Cash and Cash Equivalents | $107.6 million | $78.5 million |
| Short-Term Investments | $42.1 million | $79.7 million |
| Total Assets | $243.9 million | $276.7 million |
| Accumulated Deficit | $(635.7) million | $(614.7) million |
Liquidity: Total cash, cash equivalents, and short-term investments totaled $149.7 million as of March 31, 2008. The company expects these resources to satisfy funding requirements for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Increase: Revenues increased to $1.8 million from $0.1 million year-over-year. This was driven by a $1.0 million milestone from GSK related to the CRF program and $0.7 million in amortized license fees from DSP.
- Expense Reduction: Research and development (R&D) expenses decreased to $14.2 million from $19.1 million, primarily due to cost savings from a restructuring program initiated in Q4 2007 (reducing staff by ~125 employees) and lower external development costs.
- Net Loss Improvement: Net loss narrowed to $21.1 million from $25.7 million, reflecting the reduction in operating expenses.
- Investment Portfolio: Short-term investments decreased significantly due to maturities and sales, though the company holds $22.6 million in par value of auction rate securities (ARS) which are currently illiquid.
Outlook, Risks, and Unusual Items
Restructuring and Retention
In Q1 2008, the company recorded an additional net charge of $2.1 million for severance related to executives and personnel departing. The company expects the restructuring to reduce annual expenses by approximately $19.0 million. Additionally, a $3.2 million employee retention program was approved, with 60% paid in Q1 2008.
Investment Liquidity Risk (Auction Rate Securities)
The company holds $22.6 million (par value) in AAA-rated auction rate securities (ARS) backed by student loans. Due to global credit market issues, these securities have experienced failed auctions and are currently illiquid. The company recorded an unrealized loss of approximately $1.0 million in accumulated other comprehensive loss, reducing the carrying value to $21.6 million. While the company does not need to access these funds for operations in the foreseeable future, it may be unable to liquidate them without a potential loss of principal.
Regulatory and Litigation Risks
- Indiplon: The company ceased all indiplon clinical development activities in the U.S. following a 2007 FDA "Approvable Letter" that set forth new requirements (clinical trials in the elderly, safety studies, and pregnancy studies). There is significant uncertainty regarding the future development and commercialization of indiplon.
- Securities Litigation: A consolidated class action lawsuit and a shareholder derivative suit are pending, alleging false statements regarding the progress of indiplon. A motion to dismiss was filed in January 2008, with a hearing held in April 2008; no ruling has been issued.
Future Funding
The company expects to incur operating losses for the foreseeable future. While current capital is sufficient for 12 months, additional funding will be required for future R&D, clinical trials, and commercialization. This may be sought through strategic alliances, equity sales, or debt financing.
Key Facts for Investor Verification
- Indiplon Status: Verify the outcome of the scheduled Q2 2008 meeting with the FDA regarding the new requirements for indiplon approval and the likelihood of refiling the NDA.
- ARS Liquidity: Monitor the status of the $22.6 million auction rate securities portfolio for potential impairment charges if the market does not recover or if the company needs to liquidate.
- Restructuring Savings: Track whether the anticipated $19.0 million in annual expense savings from the Q4 2007 restructuring is being realized in subsequent quarters.
- Litigation Outcome: Watch for the court's ruling on the motion to dismiss the securities class action lawsuit, which could result in significant costs or management distraction.
- Cash Burn Rate: Assess the sustainability of the current cash position ($149.7 million) against the projected R&D spend and the timeline for potential product approvals.